The CNS Market Outlook to 2011

Psychiatric and neurological disorders constitute as much as 35%of the disease burden in the seven major pharmaceutical markets, representing continuing opportunities for pharma companies in the CNS market. However, the increasing presence of generic products coupled with low levels of innovative launches has resulted in a slowdown in market growth and considerable unmet need across the spectrum of CNS disorders. ‘The CNS Market Outlook to 2011’ provides comprehensive epidemiological analysis of the major CNS indications and key factors impacting market and competitive dynamics. This report will enable you to identify growth brands, key drug classes and leading companies through to 2011 ,pin-pointing market trends that will influence future sales of treatments within the CNS market. Evaluate changes in the competitive positions of the leading companies in the CNS market and ensure your R&D pipeline is aligned with future market opportunity to maximize commercial success.

Published: November 2006 Format PDF
Table of Contents
Full Table of Contents
Price: $2,875.00 / GBP1,437.50